argenx is betting that its lead drug VYVGART can move beyond one rare disease and become a platform treatment across several autoimmune conditions. The upside comes from a steady stream of upcoming study results and new uses, but the story can also break if trials disappoint or drug-pricing pressure intensifies.Read more
argenx leans heavily on one fast-growing autoimmune drug, and its next wave of trial results and new patient access could decide whether it becomes a broader multi-product story. But tougher rivals and growing pressure from discounts and reimbursement rules could squeeze what the company keeps from each sale.Read more
argenx leans heavily on its Vyvgart medicine, and growing pushback on drug pricing plus copycat alternatives could squeeze what it earns on each patient over time. At the same time, new treatments in development and investments in making and delivering its drugs could help it rely less on one product and keep growth going.Read more
argenx’s lead treatment for autoimmune disease is catching on faster than many expected, helped by an easier way to take it and new uses rolling out in more countries. The bigger story is whether its new AI-aided research push and growing demand from an aging population can keep growth going even as pricing, regulators, and new rivals raise the stakes.Read more
No trending discussion available.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
